Literature DB >> 2483152

Characterization of a CD4(L3T4)-positive cytotoxic T cell clone that is restricted by class I major histocompatibility complex antigen on FBL-3 tumor cell.

Y Matsubayashi1, K Zenita, A Morioka, M Iwashiro, T Masuda, H Uchino, T Fujita, K Kuribayashi.   

Abstract

An L3T4(CD4)+ CTL clone specific for Friend virus-induced tumor FBL-3 was isolated, characterized and compared with a conventional Lyt-2(CD8)+ CTL clone. This clone L3.1 was obtained from the limiting dilution culture of splenic MLTC cells from a CB6F1 mouse whose CD8+ T cells had been suppressed by an in vivo injection of anti-Lyt-2.2 mAb. The phenotype of clone L3.1 was sIg-, Thy-1.2+, L3T4(CD4)+, Lyt-2 (CD8)-, and Ia- as determined by flow-cytometry. Northern blot analysis also confirmed that mRNA for L3T4(CD4), but not for Lyt-2 (CD8) was present in the total RNA of L3.1. The FBL-3-specific killing activity of L3.1 was inhibited by anti-H-2D6 mAb, and the tumor cells did not express class II MHC antigen, indicating that the recognition of tumor antigen by this CD4+ CTL clone was restricted by the class I MHC molecule on the tumor cells. Furthermore, the finding that anti-L3T4(CD4) mAb GK1.5 inhibited the specific and lectin-dependent non-specific cytotoxicity of L3.1 suggested that CD4 molecules on this CTL clone are not ligand (MHC class II)-binding proteins, but are involved in signal transduction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2483152     DOI: 10.1016/S0171-2985(89)80028-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  3 in total

1.  Immunological characterization of tumor-rejection antigens on ultraviolet-light-induced tumors originating in the CB6F1 mouse.

Authors:  T Kitajima; M Iwashiro; K Kuribayashi; S Imamura
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

2.  Mechanism of the rejection of major histocompatibility complex class I-disparate murine skin grafts: rejection can be mediated by CD4+ cells activated by allo-class I + II antigen in CD8+ cell-depleted hosts.

Authors:  E Kobayashi; K Kawai; Y Ikarashi; M Fujiwara
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

3.  Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients.

Authors:  S Mizobata; H Tanimura; H Yamaue; M Tani; T Tsunoda; M Iwahashi; K Noguchi; N Nishimoto; T Hotta; K Arii
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.